|MDACC Study No:||2013-0207 (clinicaltrials.gov NCT No: NCT01891344)|
|Title:||A Phase 2, Open-Label Study of Rucaparib in Patients with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|
|Principal Investigator:||Robert Coleman|
|Study Description:||The goal of this clinical research study is to learn if the experimental drug |
CO-338 (rucaparib) can help to control epithelial ovarian, fallopian tube,
and/or primary peritoneal cancer. Researchers also want to learn if biomarkers
(substances in the body including DNA and RNA [the genetic materials in cells])
may be related to your reaction to the study drug. These tests may help
researchers in the future predict who may or may not respond to the study drug.
The safety of the drug will also be studied.